TriangleElrantamab (NCT06483100)
Elrantamab trial for Multiple Myeloma (NCT06483100). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with IgG or IgA myeloma responding to frontline therapy but still testing positive for residual disease after autologous transplant. Previous BCMA treatment excludes participation.
The idea: elranatamab links T cells to myeloma cells. Injections under the skin become less frequent over time. After at least twelve months, two consecutive negative marrow tests allow treatment to stop. Residual disease returning can trigger retreatment; clinical progression ends study participation.
This phase 2 study plans 65 patients. Michael Slade leads at Washington University in St. Louis, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.